More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Precision Nanomedicines

We are developing nanomedicines to target precision agents to disease sites, including to cancer metastases. Many cancer drugs, even newer personalized medicines, cause side effects that limit their effectiveness. We synthesized nanoparticle platforms to target many different classes of drugs to blood vessels that feed tumors. One of our new technologies targets nanoparticle drug carriers to P-selectin, a protein on tumor vessels that can be induced by low doses of radiotherapy, allowing us to target nearly any type of tumor.

We found that these nanoparticles can target tumors, reduce the side effects of chemotherapeutic and precision medicines, and vastly increase their anti-tumor effects.

We are also synthesizing nanoparticles that specifically target the kidneys. These will facilitate the development of new medicines to address many types of kidney diseases.


Hacking Metastasis: Nanotechnology Researchers Find New Way to Target Tumors

Nanoparticles Help Drugs Target Head and Neck Cancers with Reduced Side Effects

Miniature Device Could Unlock the Promise of Some Kidney Cancer Drugs


Y Shamay, J Shah, DF Tschaharganeh, D Roxbury, J Budhathoki-Uprety, M Işık, A Mizrachi, K Nawaly, JL Sugarman, E Baut, MR Neiman, DC Johnson, R Sridharan, KL Chu, VK Rajasekhar, JD Chodera, SW Lowe, DA Heller*, “Quantitative Self-Assembly Prediction Yields Targeted Nanomedicines” Nature Materials (2018)

RM Williams, J Shah, HS Tian, Xi Chen, F Geissman, EA Jaimes, DA Heller*, “Selective Nanoparticle Targeting of the Renal Tubules.” Hypertension (2017) In press.

A Mizrachi, Y Shamay, J Shah, S Brook, J Soong, V Rajasekhar, J Humm, J Healey, S Powell, J Baselga, DA Heller*, A Haimovitz-Friedman*, M Scaltriti*: “Tumor-specific PI3K inhibition via nanoparticle delivery in head and neck squamous cell carcinoma.” Nature Communications 8 (2017) 14292.

Yosef Shamay, Moshe Elkabets, Hongyan Li, Janki Shah, Samuel Brook, Feng Weng, Keren Adler, Emily Baut, Maurizio Scaltriti, Prakrit V. Jena, Eric E. Gardner, John T. Poirier, Charles M. Rudin, Jose Baselga, Adriana Haimovitz-Friedman, Daniel A. Heller: ”P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.” June 29, 2016 8 345ra87

RM Williams, J Shah, BD Ng, DR Minton, LJ Gudas, C Park, DA. Heller*: “Mesoscale Nanoparticles Selectively Target the Renal Proximal Tubule Epithelium.” Nano Letters 15 (2015) 2358-2364.